In the present study, we initially evaluated the potential role of B7-family molecules CD80 and CD86 during resolution of disease (i.e. after virus clearance) by in vivo administration of a blocking monoclonal antibody directed to CD80 or CD86at day 8 post infection (p.i.), a time point shortly after IAV clearance within the respiratory tract [17]. This evidence concerns the gene CD80 and infection.